Donald Benefield, MD
Ophthalmology · Gulfport, MSNPI 1386636694
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.5% of the total across 271 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AbbVie at 32.3% of the total.
Across 271 payments — averaging $23.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson Surgical Vision, Inc.$727
- Alcon$658
- Mallinckrodt Hospital Products Inc.$550
- Amgen$302
- Bausch & Lomb, A Division Of Bausch Health US, LLC$277
- plus $2K from 23 others
What the payments were for
- Food & beverage$5,79592%
- Education$4718%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 101 | $2,022 |
| Johnson & Johnson Surgical Vision, Inc. | 18 | $727 |
| Alcon | 18 | $658 |
| Mallinckrodt Hospital Products Inc. | 17 | $550 |
| Amgen(2 entities) | 17 | $302 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 19 | $277 |
| Tarsus Pharmaceuticals, Inc. | 6 | $250 |
| Oyster Point Pharma, Inc. | 7 | $165 |
| Bausch & Lomb Americas Inc. | 8 | $149 |
| Biotissue Holdings Inc. | 8 | $142 |
| Alimera Sciences, Inc. | 7 | $133 |
| ANI Pharmaceuticals, Inc. | 6 | $107 |
| Glaukos Corporation | 4 | $99 |
| Dompe US, Inc. | 3 | $90 |
| Sun Pharmaceutical Industries Inc. | 5 | $84 |
| Kala Pharmaceuticals, Inc. | 4 | $69 |
| Ocular Therapeutix, Inc. | 3 | $52 |
| Aerie Pharmaceuticals, Inc. | 3 | $50 |
| Iridex Corporation | 2 | $46 |
| Novartis | 2 | $36 |
| Shire North American Group Inc | 2 | $35 |
| Beaver-visitec International, Inc. | 2 | $35 |
| Rayner Intraocular Lenses Limited | 1 | $35 |
| Apellis Pharmaceuticals, Inc. | 1 | $31 |
| Harrow Eye, LLC | 1 | $31 |
| Johnson & Johnson Vision Care, Inc. | 2 | $27 |
| Sight Sciences, Inc. | 2 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Eyevance Pharmaceuticals LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XDEMVY$125
- Tecnis Simplicity$125
- Clareon PanOptix Pro$109
How this compares
$6,266 in reported general payments places this provider in the 85th percentile of 150 ophthalmology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EyleaAflibercept | 31 | $81,400 |
| RestasisCyclosporine | 87 | $65,446 |
| MieboPerfluorohexyloctane/Pf | 34 | $26,511 |
| XiidraLifitegrast | 30 | $23,015 |
| LumiganBimatoprost | 46 | $18,009 |
| Cyclosporine | 31 | $12,693 |
| CombiganBrimonidine Tartrate/Timolol | 32 | $11,741 |
| Prednisolone Acetate | 156 | $7,149 |
| RocklatanNetarsudil Mesylat/Latanoprost | 11 | $5,074 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 279 | $3,967 |
| Latanoprost | 435 | $3,780 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 15 | $2,109 |
| Acetazolamide | 45 | $1,952 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 21 | $1,179 |
| Dorzolamide Hcl | 67 | $1,062 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $2,022 | $95,197165 claims |
| Regeneron Healthcare Solutions, Inc.Eylea | $22 | $81,40031 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $149 | $49,52664 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $50 | $5,07411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 150 ophthalmology providers in Mississippi.
Other ophthalmology in Gulfport
- Philip BertucciGulfport$4K
- Kiper NelsonHattiesburg$234K
- John ParkerTupelo$72K
- Joseph ChildsTupelo$42K
- Heather HancockJackson$39K
- Leslie AdenFlowood$38K
- Adam QuinnHattiesburg$29K
- Mark KoskoJackson$27K
- James ShippOxford$21K
- Calvin BrownOlive Branch$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.